期刊
AMERICAN JOURNAL OF OPHTHALMOLOGY
卷 152, 期 6, 页码 1044-1052出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajo.2011.05.028
关键词
-
资金
- National Eye Institute, National Institutes of Health, Bethesda, Maryland [U10 EY 014655]
- Johns Hopkins University Bloomberg School of Public Health [U10 EY 014660]
- University of Wisconsin, Madison, School of Medicine [U10 EY 014656]
- Abbott Laboratories
- Alcon Laboratories
- Allergan Pharmaceutical Corporation
- Applied Genetic Technologies Corporation
- Corcep Therapeutics
- Genentech, Inc
- Genzyme Corporation
- GlaxoSmithKline
- Novartis Pharmaceuticals Corporation
- Roche Pharmaceuticals
- Bausch Lomb
- ACIONT, Inc.
PURPOSE: To identify a clinically meaningful threshold for change in retinal thickness measured by optical coherence tomography for patients with uveitic macular edema using correlation with change in visual acuity. DESIGN: Cross-sectional and longitudinal study. METHODS: One hundred twenty-eight eyes (101 individuals) with macular edema enrolled in the Multicenter Uveitis Steroid Treatment (MUST) trial. At enrollment and after 6 months of follow-up, retinal thickness was measured at the central subfield with time-domain optical coherence tomography and visual acuity was measured with logarithmic (Early Treatment Diabetic Retinopathy Study) visual acuity charts. Participants were classified as having macular edema if the retinal thickness was 260 mu m or more. RESULTS: A threshold for change in retinal center subfield thickness of 20% balanced the percentage of false positives and false negatives for predicting more than a 10-letter change in visual acuity with a sensitivity of 77% and a specificity of 75%. The results were similar for more than 5-letter changes and for 15-letter or more changes. Those with a 20% or more reduction in retinal thickness had a mean 11.0-letter improvement (95% confidence interval, 7.7 to 14.3) as compared with a -0.4-letter change (95% confidence interval, -4.1 to 3.3) in visual acuity for those without a 20% reduction (P < .01). CONCLUSIONS: In addition to being above the level of measurement uncertainty, a 20% change in retinal thickness in patients with macular edema seems to be optimal for clinically important changes in visual acuity and may be considered as an outcome for clinical trials of treatments for uveitic macular edema. (Am J Ophthalmol 2011;152:1044-1052. (C) 2011 by Elsevier Inc. All rights reserved.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据